Registro e Iniciativa Europea/Internacional de Displasia Fibromuscular (FEIRI)

Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de inupadenant en combinación con carboplatino y pemetrexed en adultos con cáncer de pulmón no microcítico y no epidermoide que han progresado con la inmunoterapia.

Estudio fase II de un solo brazo sobre la eficacia y la seguridad de la combinación de trastuzumab, TUCAtinib y viNorelbina en pacientes con cáncer de mama localmente avanzado no resecable o metastásico HER2-positivo. Estudio TrasTUCAN

A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Estudio observacional retrospectivo multicéntrico: Manejo del Cáncer No Microcítico de Pulmón (CNMP) Estadio III en España. Registro del GOECP/SEOR

Follow-up in Gynecological Cancer Survivors: An EORTC QLG-GCG Survivorship Study

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Switching to AZD9833 (a Next Generation, Oral SERD) vs Continuing Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in patients with HR+/HER2- early breast cancer and an intermediate or high risk of recurrence who have completed definitive loco regional therapy and at least 2 years of adjuvant endocrine therapy without disease recurrence.

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers following 1 prior line of platinum-based chemotherapy